Turn Therapeutics director granted 95,000 options
Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments starting on June 30, 2026, contingent on his continued employment under the company’s 2025 Omnibus Incentive Plan. This is a compensation-related award, not an open-market share purchase or sale.
Insider Trade Summary
Grant/Award: 95,000 shares
Grant/Award
1 txn
Insider
Gengos Andrew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 95,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 95,000 contracts (Direct)
Footnotes (1)
- F1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Key Figures
Options granted: 95,000 options
Exercise price: $5.75 per share
Underlying shares: 95,000 shares
+2 more
5 metrics
Options granted
95,000 options
Stock option grant to director on June 4, 2026
Exercise price
$5.75 per share
Strike price for the 95,000 stock options
Underlying shares
95,000 shares
Common stock underlying the granted options
Expiration date
June 4, 2036
Option term end date
Vesting schedule
12 equal monthly installments
Vesting begins June 30, 2026, subject to continued employment
Key Terms
Stock option (right to buy), exercise price, vesting, Omnibus Incentive Plan, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 5.7500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option will vest in twelve (12) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Omnibus Incentive Plan financial
"Issuer's 2025 Omnibus Incentive Plan"
An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Turn Therapeutics (TTRX) director Andrew Gengos report on this Form 4?
Andrew Gengos reported receiving a grant of stock options for 95,000 shares of Turn Therapeutics common stock. These options are a compensation award, not an open-market trade, and give him the right to buy shares later at a fixed exercise price.
How many Turn Therapeutics (TTRX) options were granted and at what exercise price?
The grant covers 95,000 stock options with an exercise price of $5.75 per share. This means Gengos can choose to buy up to 95,000 shares at $5.75 each in the future, regardless of the market price at that time.
When do Andrew Gengos’s Turn Therapeutics (TTRX) options vest?
The options vest in twelve equal monthly installments starting on June 30, 2026. Each month, a portion becomes exercisable, as long as Gengos remains employed and continues to meet the conditions of the 2025 Omnibus Incentive Plan governing the award.
When do the Turn Therapeutics (TTRX) stock options granted to Andrew Gengos expire?
The options expire on June 4, 2036, giving a long-term window to exercise. After that date, any unexercised options become worthless and can no longer be used to buy Turn Therapeutics common shares at the fixed exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
